Organovo Holdings ( (ONVO) ) just unveiled an update.

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Organovo (ONVO) announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured ...

Organovo Holdings (NASDAQ:ONVO), Inc., a biotechnology firm specializing in biological products, has announced an expansion of its equity incentive plan, following approval from its stockholders.

Organovo Holdings (NASDAQ:ONVO), Inc., a biotechnology firm specializing in biological products, has announced an expansion of its equity incentive plan, following approval from its stockholders.

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology company specializing in novel treatments for inflammatory bowel disease and other conditions, announced significant findings from ...

Building on its commitment to addressing health inequities, Blue Cross Blue Shield of Massachusetts (Blue Cross) today announced the distribution of new grants to five not-for-profit organizations as ...